TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc.

Oppenheimer analyst Suraj Kalia maintained a Buy rating on TransMedics Group today and set a price target of $150.00. The company’s shares opened t...

Oppenheimer Remains a Buy on TransMedics Group (TMDX)

Transmedics Group (($TMDX)) has held its Q3 earnings call. Read on for the main highlights of the call. TransMedics Group’s recent earnings call re...

TransMedics Group’s Earnings Call Highlights Robust Growth and Strategic Expansion

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MiMedx Group (MDXG – Research Report), TransMedics Group (TMDX – ...

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), TransMedics Group (TMDX) and Arcus Biosciences (RCUS)

Transmedics Group ( ($TMDX) ) has released its Q3 earnings. Here is a breakdown of the information Transmedics Group presented to its investors. Tr...

TransMedics Group Reports Strong Q3 2025 Results

Jefferies analyst Young Li maintained a Buy rating on TransMedics Group today and set a price target of $145.00. The company’s shares opened today ...

Jefferies Sticks to Its Buy Rating for TransMedics Group (TMDX)

Transmedics Group (($TMDX)) announced an update on their ongoing clinical study. Study Overview: The US National OCS Heart Perfusion (OHP) Registry...

Market Cap	$4.17B	P/E Ratio	50.16
52W High	$145.50	52W Low	$55.00
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	38.7%	52W Position	83.9%
Overall Score	55	Value Score	20
Quality Score	--	Technical Score	90

EPS Current Est	$2.61	EPS Next Est	$2.67
EPS Growth Est	+2.3%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TMDX	$130.93	+5.74%	910.34K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TMDX	$130.93	+5.7%	910.34K
3
4
5
6

TMDX

TMDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get TransMedics Group Inc. Data in Excel

Get TransMedics Group Inc. Data in Excel